Enable job alerts via email!
Boost your interview chances
A leading university in Chicago is seeking a Visiting Research Assistant Professor to engage in cutting-edge research targeting Alzheimer’s Disease via chemokine receptor antagonists. This role offers an opportunity to work on significant therapeutics development, in collaboration with experienced researchers in a well-funded environment.
Join to apply for the Visiting Research Assistant Professor role at University of Illinois College of Medicine.
Continue with Google
2 days ago Be among the first 25 applicants.
About the University of Illinois Chicago: UIC is among the nation’s preeminent urban public research universities, a Carnegie RU/VH research institution, and the largest university in Chicago. UIC serves over 34,000 students, with a diverse student body, and is designated as a Minority Serving Institution (MSI), an Asian American and Native American Pacific Islander Serving Institution (AANAPSI), and a Hispanic Serving Institution (HSI). It offers multidisciplinary academic programs across 16 colleges, including health sciences, and emphasizes cutting-edge research and student success. UIC is ranked among top public schools and national universities by U.S. News & World Report. It has over 300,000 alumni and is one of Chicago’s largest employers. Benefits include health, dental, vision, life, disability insurance, a pension plan, paid leave, and tuition waivers for employees and dependents.
Position Summary: The laboratory of Dr. Steven J. Ackerman, in collaboration with labs of Drs. Vadim Gaponenko, Sojin Shikano, and Jalees Rehman in the Department of Biochemistry and Molecular Genetics, seeks a motivated Visiting Research Assistant Professor (RAP). The role involves developing chemokine receptor biased antagonists targeting neuroinflammation, neurodegeneration, and memory loss in Alzheimer’s Disease (AD). The project is funded by the Alzheimer’s Drug Development Foundation (ADDF)-Harrington Foundation Scholar Award, focusing on CCR3-targeting peptides and small molecule antagonists as therapeutics. The RAP will work on these therapeutics and other projects related to chemokine receptors in AD. Labs links: Ackerman Lab, Gaponenko Lab, Shikano Lab, Rehman Lab.